@saibolla/ada 0.1.2

package/skills/clinical-decision-support/references/treatment_recommendations.md

@@ -0,0 +1,521 @@
+# Treatment Recommendations Guide
+
+## Overview
+
+Evidence-based treatment recommendations provide clinicians with systematic guidance for therapeutic decision-making. This guide covers the development, grading, and presentation of clinical recommendations in pharmaceutical and healthcare settings.
+
+## Evidence Grading Systems
+
+### GRADE (Grading of Recommendations Assessment, Development and Evaluation)
+
+**Quality of Evidence Levels**
+
+**High Quality (⊕⊕⊕⊕)**
+- Further research very unlikely to change confidence in estimate
+- Criteria: Well-designed RCTs with consistent results, no serious limitations
+- Example: Multiple large RCTs showing similar treatment effects
+
+**Moderate Quality (⊕⊕⊕○)**
+- Further research likely to have important impact on confidence
+- Criteria: RCTs with limitations OR very strong evidence from observational studies
+- Example: Single RCT or multiple RCTs with some inconsistency
+
+**Low Quality (⊕⊕○○)**
+- Further research very likely to have important impact on confidence
+- Criteria: Observational studies OR RCTs with serious limitations
+- Example: Case-control studies, cohort studies with confounding
+
+**Very Low Quality (⊕○○○)**
+- Estimate of effect very uncertain
+- Criteria: Case series, expert opinion, or very serious limitations
+- Example: Mechanistic reasoning, unsystematic clinical observations
+
+**Strength of Recommendation**
+
+**Strong Recommendation (Grade 1)**
+- Benefits clearly outweigh risks and burdens (or vice versa)
+- Wording: "We recommend..."
+- Implications: Most patients should receive recommended course
+- Symbol: ↑↑ (strong for) or ↓↓ (strong against)
+
+**Conditional/Weak Recommendation (Grade 2)**
+- Trade-offs exist; benefits and risks closely balanced
+- Wording: "We suggest..."
+- Implications: Different choices for different patients; shared decision-making
+- Symbol: ↑ (weak for) or ↓ (weak against)
+
+**GRADE Notation Examples**
+- **1A**: Strong recommendation, high-quality evidence
+- **1B**: Strong recommendation, moderate-quality evidence
+- **2A**: Weak recommendation, high-quality evidence
+- **2B**: Weak recommendation, moderate-quality evidence
+- **2C**: Weak recommendation, low- or very low-quality evidence
+
+### Oxford Centre for Evidence-Based Medicine (CEBM) Levels
+
+**Level 1: Systematic Review/Meta-Analysis**
+- 1a: SR of RCTs
+- 1b: Individual RCT with narrow confidence interval
+- 1c: All-or-none studies (all patients died before treatment, some survive after)
+
+**Level 2: Cohort Studies**
+- 2a: SR of cohort studies
+- 2b: Individual cohort study (including low-quality RCT)
+- 2c: Outcomes research, ecological studies
+
+**Level 3: Case-Control Studies**
+- 3a: SR of case-control studies
+- 3b: Individual case-control study
+
+**Level 4: Case Series**
+- Case series, poor-quality cohort, or case-control studies
+
+**Level 5: Expert Opinion**
+- Mechanism-based reasoning, expert opinion without critical appraisal
+
+**Grades of Recommendation**
+- **Grade A**: Consistent level 1 studies
+- **Grade B**: Consistent level 2 or 3 studies, or extrapolations from level 1
+- **Grade C**: Level 4 studies or extrapolations from level 2 or 3
+- **Grade D**: Level 5 evidence or inconsistent/inconclusive studies
+
+## Treatment Sequencing and Line-of-Therapy
+
+### First-Line Therapy
+
+**Selection Criteria**
+- **Standard of Care**: Guideline-recommended based on phase 3 trials
+- **Patient Factors**: Performance status, comorbidities, organ function
+- **Disease Factors**: Stage, molecular profile, aggressiveness
+- **Goals**: Cure (adjuvant/neoadjuvant), prolonged remission, symptom control
+
+**First-Line Options Documentation**
+```
+First-Line Treatment Options:
+
+Option 1: Regimen A (NCCN Category 1, ESMO I-A)
+- Evidence: Phase 3 RCT (n=1000), median PFS 12 months vs 8 months (HR 0.6, p<0.001)
+- Population: PD-L1 ≥50%, EGFR/ALK negative
+- Toxicity Profile: Immune-related AEs (15% grade 3-4)
+- Recommendation Strength: 1A (strong, high-quality evidence)
+
+Option 2: Regimen B (NCCN Category 1, ESMO I-A)
+- Evidence: Phase 3 RCT (n=800), median PFS 10 months vs 8 months (HR 0.7, p=0.003)
+- Population: All patients, no biomarker selection
+- Toxicity Profile: Hematologic toxicity (25% grade 3-4)
+- Recommendation Strength: 1A (strong, high-quality evidence)
+```
+
+### Second-Line and Beyond
+
+**Second-Line Selection**
+- **Prior Response**: Duration of response to first-line
+- **Progression Pattern**: Oligoprogression vs widespread progression
+- **Residual Toxicity**: Recovery from first-line toxicities
+- **Biomarker Evolution**: Acquired resistance mechanisms
+- **Clinical Trial Availability**: Novel agents in development
+
+**Treatment History Documentation**
+```
+Prior Therapies:
+1. First-Line: Pembrolizumab (12 cycles)
+   - Best Response: Partial response (-45% tumor burden)
+   - PFS: 14 months
+   - Discontinuation Reason: Progressive disease
+   - Residual Toxicity: Grade 1 hypothyroidism (on levothyroxine)
+
+2. Second-Line: Docetaxel + ramucirumab (6 cycles)
+   - Best Response: Stable disease
+   - PFS: 5 months  
+   - Discontinuation Reason: Progressive disease
+   - Residual Toxicity: Grade 2 peripheral neuropathy
+
+Current Consideration: Third-Line Options
+- Clinical trial vs platinum-based chemotherapy
+```
+
+### Maintenance Therapy
+
+**Indications**
+- Consolidation after response to induction therapy
+- Prevention of progression without continuous cytotoxic treatment
+- Bridging to definitive therapy (e.g., transplant)
+
+**Evidence Requirements**
+- PFS benefit demonstrated in randomized trials
+- Tolerable long-term toxicity profile
+- Quality of life preserved or improved
+
+## Biomarker-Guided Therapy Selection
+
+### Companion Diagnostics
+
+**FDA-Approved Biomarker-Drug Pairs**
+
+**Required Testing (Treatment-Specific)**
+- **ALK rearrangement → Alectinib, Brigatinib, Lorlatinib** (NSCLC)
+- **EGFR exon 19 del/L858R → Osimertinib** (NSCLC)
+- **BRAF V600E → Dabrafenib + Trametinib** (Melanoma, NSCLC, CRC)
+- **HER2 amplification/3+ → Trastuzumab, Pertuzumab** (Breast, Gastric)
+- **PD-L1 ≥50% → Pembrolizumab monotherapy** (NSCLC first-line)
+
+**Complementary Diagnostics (Informative but not Required)**
+- **PD-L1 1-49%**: Combination immunotherapy preferred
+- **TMB-high**: May predict immunotherapy benefit (investigational)
+- **MSI-H/dMMR**: Pembrolizumab approved across tumor types
+
+### Biomarker Testing Algorithms
+
+**NSCLC Biomarker Panel**
+```
+Reflex Testing at Diagnosis:
+✓ EGFR mutations (exons 18, 19, 20, 21)
+✓ ALK rearrangement (IHC or FISH)
+✓ ROS1 rearrangement (FISH or NGS)
+✓ BRAF V600E mutation
+✓ PD-L1 IHC (22C3 or SP263)
+✓ Consider: Comprehensive NGS panel
+
+If EGFR+ on Osimertinib progression:
+✓ Liquid biopsy for T790M (if first/second-gen TKI)
+✓ Tissue biopsy for resistance mechanisms
+✓ MET amplification, HER2 amplification, SCLC transformation
+```
+
+**Breast Cancer Biomarker Algorithm**
+```
+Initial Diagnosis:
+✓ ER/PR IHC
+✓ HER2 IHC and FISH (if 2+)
+✓ Ki-67 proliferation index
+
+If Metastatic ER+/HER2-:
+✓ ESR1 mutations (liquid biopsy after progression on AI)
+✓ PIK3CA mutations (for alpelisib eligibility)
+✓ BRCA1/2 germline testing (for PARP inhibitor eligibility)
+✓ PD-L1 testing (if considering immunotherapy combinations)
+```
+
+### Actionable Alterations
+
+**Tier I: FDA-Approved Targeted Therapy**
+- Strong evidence from prospective trials
+- Guideline-recommended
+- Examples: EGFR exon 19 deletion, HER2 amplification, ALK fusion
+
+**Tier II: Clinical Trial or Off-Label Use**
+- Emerging evidence, clinical trial preferred
+- Examples: NTRK fusion (larotrectinib), RET fusion (selpercatinib)
+
+**Tier III: Biological Plausibility**
+- Preclinical evidence only
+- Clinical trial enrollment strongly recommended
+- Examples: Novel kinase fusions, rare resistance mutations
+
+## Combination Therapy Protocols
+
+### Rationale for Combinations
+
+**Mechanisms**
+- **Non-Overlapping Toxicity**: Maximize dose intensity of each agent
+- **Synergistic Activity**: Enhanced efficacy beyond additive effects
+- **Complementary Mechanisms**: Target multiple pathways simultaneously
+- **Prevent Resistance**: Decrease selection pressure for resistant clones
+
+**Combination Design Principles**
+- **Sequential**: Induction then consolidation (different regimens)
+- **Concurrent**: Administered together for synergy
+- **Alternating**: Rotate regimens to minimize resistance
+- **Intermittent**: Pulse dosing vs continuous exposure
+
+### Drug Interaction Assessment
+
+**Pharmacokinetic Interactions**
+- **CYP450 Induction/Inhibition**: Check for drug-drug interactions
+- **Transporter Interactions**: P-gp, BCRP, OATP substrates/inhibitors
+- **Protein Binding**: Highly protein-bound drugs (warfarin caution)
+- **Renal/Hepatic Clearance**: Avoid multiple renally cleared agents
+
+**Pharmacodynamic Interactions**
+- **Additive Toxicity**: Avoid overlapping adverse events (e.g., QTc prolongation)
+- **Antagonism**: Ensure mechanisms are complementary, not opposing
+- **Dose Modifications**: Pre-defined dose reduction schedules for combinations
+
+### Combination Documentation
+
+```
+Combination Regimen: Drug A + Drug B
+
+Rationale:
+- Phase 3 RCT demonstrated PFS benefit (16 vs 11 months, HR 0.62, p<0.001)
+- Complementary mechanisms: Drug A (VEGF inhibitor) + Drug B (immune checkpoint inhibitor)
+- Non-overlapping toxicity profiles
+
+Dosing:
+- Drug A: 10 mg/kg IV every 3 weeks
+- Drug B: 1200 mg IV every 3 weeks
+- Continue until progression or unacceptable toxicity
+
+Key Toxicities:
+- Hypertension (Drug A): 30% grade 3-4, manage with antihypertensives
+- Immune-related AEs (Drug B): 15% grade 3-4, corticosteroid management
+- No significant pharmacokinetic interactions observed
+
+Monitoring:
+- Blood pressure: Daily for first month, then weekly
+- Thyroid function: Every 6 weeks  
+- Liver enzymes: Before each cycle
+- Imaging: Every 6 weeks (RECIST v1.1)
+```
+
+## Monitoring and Follow-up Schedules
+
+### On-Treatment Monitoring
+
+**Laboratory Monitoring**
+```
+Test                   Baseline  Cycle 1  Cycle 2+  Rationale
+CBC with differential  ✓         Weekly   Day 1     Myelosuppression risk
+Comprehensive panel    ✓         Day 1    Day 1     Electrolytes, renal, hepatic
+Thyroid function       ✓         -        Q6 weeks  Immunotherapy
+Lipase/amylase        ✓         -        As needed Pancreatitis risk
+Troponin/BNP          ✓*        -        As needed Cardiotoxicity risk
+(*if cardiotoxic agent)
+```
+
+**Imaging Assessment**
+```
+Modality           Baseline  Follow-up           Criteria
+CT chest/abd/pelvis ✓       Every 6-9 weeks     RECIST v1.1
+Brain MRI          ✓*       Every 12 weeks      If CNS metastases
+Bone scan          ✓**      Every 12-24 weeks   If bone metastases
+PET/CT             ✓***     Response assessment Lymphoma (Lugano criteria)
+(*if CNS mets, **if bone mets, ***if PET-avid tumor)
+```
+
+**Clinical Assessment**
+```
+Assessment               Frequency                Notes
+ECOG performance status  Every visit              Decline may warrant dose modification
+Vital signs              Every visit              Blood pressure for anti-VEGF agents
+Weight                   Every visit              Cachexia, fluid retention
+Symptom assessment       Every visit              PRO-CTCAE questionnaire
+Physical exam            Every visit              Target lesions, new symptoms
+```
+
+### Dose Modification Guidelines
+
+**Hematologic Toxicity**
+```
+ANC and Platelet Counts          Action
+ANC ≥1.5 AND platelets ≥100k    Treat at full dose
+ANC 1.0-1.5 OR platelets 75-100k Delay 1 week, recheck
+ANC 0.5-1.0 OR platelets 50-75k  Delay treatment, G-CSF support, reduce dose 20%
+ANC <0.5 OR platelets <50k       Hold treatment, G-CSF, transfusion PRN, reduce 40%
+
+Febrile Neutropenia              Hold treatment, hospitalize, antibiotics, G-CSF
+                                Reduce dose 20-40% on recovery, consider prophylactic G-CSF
+```
+
+**Non-Hematologic Toxicity**
+```
+Adverse Event     Grade 1         Grade 2              Grade 3              Grade 4
+Diarrhea          Continue        Continue with        Hold until ≤G1,      Hold, hospitalize
+                                 loperamide           reduce 20%           Consider discontinuation
+Rash              Continue        Continue with        Hold until ≤G1,      Discontinue
+                                 topical Rx           reduce 20%
+Hepatotoxicity    Continue        Repeat in 1 wk,      Hold until ≤G1,      Discontinue permanently
+                                 hold if worsening    reduce 20-40%
+Pneumonitis       Continue        Hold, consider       Hold, corticosteroids, Discontinue, high-dose
+                                 corticosteroids      discontinue if no improvement steroids
+```
+
+### Post-Treatment Surveillance
+
+**Disease Monitoring**
+```
+Time After Treatment    Imaging Frequency        Labs                   Clinical
+Year 1                  Every 3 months          Every 3 months         Every 3 months
+Year 2                  Every 3-4 months        Every 3-4 months       Every 3-4 months
+Years 3-5               Every 6 months          Every 6 months         Every 6 months
+Year 5+                 Annually               Annually               Annually
+
+Earlier imaging if symptoms suggest recurrence
+```
+
+**Survivorship Care**
+```
+Surveillance              Frequency                     Duration
+Disease monitoring        Per schedule above            Lifelong or until recurrence
+Late toxicity screening   Annually                      Lifelong
+  - Cardiac function     Every 1-2 years               If anthracycline/trastuzumab
+  - Pulmonary function   As clinically indicated        If bleomycin/radiation
+  - Neuropathy           Symptom-based                  Peripheral neuropathy history
+  - Secondary malignancy Age-appropriate screening       Lifelong (increased risk)
+Genetic counseling        One time                      If hereditary cancer syndrome
+Psychosocial support     As needed                      Depression, anxiety, PTSD screening
+```
+
+## Special Populations
+
+### Elderly Patients (≥65-70 years)
+
+**Considerations**
+- **Reduced organ function**: Adjust for renal/hepatic impairment
+- **Polypharmacy**: Drug-drug interaction risk
+- **Frailty**: Geriatric assessment (G8, VES-13, CARG score)
+- **Goals of care**: Quality of life vs survival, functional independence
+
+**Modifications**
+- Dose reductions: 20-25% reduction for frail patients
+- Longer intervals: Every 4 weeks instead of every 3 weeks
+- Less aggressive regimens: Single-agent vs combination therapy
+- Supportive care: Increased monitoring, G-CSF prophylaxis
+
+### Renal Impairment
+
+**Dose Adjustments by eGFR**
+```
+eGFR (mL/min/1.73m²)    Category  Action
+≥90                     Normal    Standard dosing
+60-89                   Mild      Standard dosing (most agents)
+30-59                   Moderate  Dose reduce renally cleared drugs 25-50%
+15-29                   Severe    Dose reduce 50-75%, avoid nephrotoxic agents
+<15 (dialysis)          ESRD      Avoid most agents, case-by-case decisions
+```
+
+**Renally Cleared Agents Requiring Adjustment**
+- Carboplatin (Calvert formula: AUC × [GFR + 25])
+- Methotrexate (reduce dose 50-75% if CrCl <60)
+- Capecitabine (reduce dose 25-50% if CrCl 30-50)
+
+### Hepatic Impairment
+
+**Dose Adjustments by Bili and AST/ALT**
+```
+Category          Bilirubin         AST/ALT        Action
+Normal           ≤ULN              ≤ULN           Standard dosing
+Mild (Child A)    1-1.5× ULN        Any            Reduce dose 25% for hepatically metabolized
+Moderate (Child B) 1.5-3× ULN       Any            Reduce dose 50%, consider alternative
+Severe (Child C)  >3× ULN           Any            Avoid most agents, case-by-case
+```
+
+**Hepatically Metabolized Agents Requiring Adjustment**
+- Docetaxel (reduce 25-50% if bilirubin elevated)
+- Irinotecan (reduce 50% if bilirubin 1.5-3× ULN)
+- Tyrosine kinase inhibitors (most metabolized by CYP3A4, reduce by 50%)
+
+### Pregnancy and Fertility
+
+**Contraception Requirements**
+- Effective contraception required during treatment and 6-12 months after
+- Two methods recommended for highly teratogenic agents
+- Male patients: Contraception if partner of childbearing potential
+
+**Fertility Preservation**
+- Oocyte/embryo cryopreservation (females, before gonadotoxic therapy)
+- Sperm banking (males, before alkylating agents, platinum)
+- GnRH agonists (ovarian suppression, controversial efficacy)
+- Referral to reproductive endocrinology before treatment
+
+**Pregnancy Management**
+- Avoid chemotherapy in first trimester (organogenesis)
+- Selective agents safe in second/third trimester (case-by-case)
+- Multidisciplinary team: oncology, maternal-fetal medicine, neonatology
+
+## Clinical Trial Considerations
+
+### When to Recommend Clinical Trials
+
+**Ideal Scenarios**
+- No standard therapy available (rare diseases, refractory settings)
+- Multiple equivalent standard options (patient preference for novel agent)
+- Standard therapy failed (second-line and beyond)
+- High-risk disease (adjuvant trials for improved outcomes)
+
+**Trial Selection Criteria**
+- **Phase**: Phase 1 (dose-finding, safety), Phase 2 (efficacy signal), Phase 3 (comparative effectiveness)
+- **Eligibility**: Match patient to inclusion/exclusion criteria
+- **Mechanism**: Novel vs established mechanism, biological rationale
+- **Sponsor**: Academic vs industry, trial design quality
+- **Logistics**: Distance to trial site, visit frequency, out-of-pocket costs
+
+### Shared Decision-Making
+
+**Informing Patients**
+- Natural history without treatment
+- Standard treatment options with evidence, benefits, risks
+- Clinical trial options (if available)
+- Goals of care alignment
+- Patient values and preferences
+
+**Decision Aids**
+- Visual representations of benefit (icon arrays)
+- Number needed to treat calculations
+- Quality of life trade-offs
+- Decisional conflict scales
+
+## Documentation Standards
+
+### Treatment Plan Documentation
+
+```
+TREATMENT PLAN
+
+Diagnosis: [Disease, stage, molecular profile]
+
+Goals of Therapy:
+☐ Curative intent
+☐ Prolonged disease control
+☑ Palliation and quality of life
+
+Recommended Regimen: [Name] (NCCN Category 1, GRADE 1A)
+
+Evidence Basis:
+- Primary study: [Citation], Phase 3 RCT, n=XXX
+- Primary endpoint: PFS 12 months vs 8 months (HR 0.6, 95% CI 0.45-0.80, p<0.001)
+- Secondary endpoints: OS 24 vs 20 months (HR 0.75, p=0.02), ORR 60% vs 40%
+- Safety: Grade 3-4 AEs 35%, discontinuation rate 12%
+
+Dosing Schedule:
+- Drug A: XX mg IV day 1
+- Drug B: XX mg PO days 1-21
+- Cycle length: 21 days
+- Planned cycles: Until progression or unacceptable toxicity
+
+Premedications:
+- Dexamethasone 8 mg IV (anti-emetic)
+- Ondansetron 16 mg IV (anti-emetic)
+- Diphenhydramine 25 mg IV (hypersensitivity prophylaxis)
+
+Monitoring Plan: [See schedule above]
+
+Dose Modification Plan: [See guidelines above]
+
+Alternative Options Discussed:
+- Option 2: [Alternative regimen], GRADE 1B
+- Clinical trial: [Trial name/number], Phase 2, novel agent
+- Best supportive care
+
+Patient Decision: Proceed with recommended regimen
+
+Informed Consent: Obtained for chemotherapy, risks/benefits discussed
+
+Date: [Date]
+Provider: [Name, credentials]
+```
+
+## Quality Metrics
+
+### Treatment Recommendation Quality Indicators
+
+- Evidence grading provided for all recommendations
+- Multiple options presented when equivalent evidence exists
+- Toxicity profiles clearly described
+- Monitoring plans specified
+- Dose modification guidelines included
+- Special populations addressed (elderly, renal/hepatic impairment)
+- Clinical trial options mentioned when appropriate
+- Shared decision-making documented
+- Goals of care aligned with treatment intensity
+